TY - JOUR
T1 - Trends in net survival from kidney cancer in six European Latin countries
T2 - Results from the SUDCAN population-based study
AU - GRELL EUROCARE-5 Working Group
AU - Mangone, Lucia
AU - Bossard, Nadine
AU - Marcos-Gragera, Rafael
AU - Pezzarossi, Annamaria
AU - Roncaglia, Francesca
AU - Rossi, Paolo Giorgi
AU - Van Eycken, E.
AU - Henau, K.
AU - Velten, M.
AU - Bouvier, V.
AU - Launoy, G.
AU - Bouvier, A. M.
AU - Faivre, J.
AU - Woronoff, A. S.
AU - Robaszkiewicz, M.
AU - Tretarre, B.
AU - Uhry, Z.
AU - Colonna, M.
AU - Molinié, F.
AU - Bara, S.
AU - Lapôtre-Ledoux, B.
AU - Grosclaude, P.
AU - Brenner, H.
AU - Katalinic, A.
AU - Mazzoleni, G.
AU - Bulatko, A.
AU - Buzzoni, C.
AU - Giacomin, A.
AU - Ferretti, S.
AU - Barchielli, A.
AU - Manneschi, G.
AU - Gatta, G.
AU - Sant, M.
AU - Amash, H.
AU - Amati, C.
AU - Baili, P.
AU - Berrino, F.
AU - Bonfarnuzzo, S.
AU - Botta, L.
AU - Capocaccia, R.
AU - Di Salvo, F.
AU - Foschi, R.
AU - Margutti, C.
AU - Meneghini, E.
AU - Minicozzi, P.
AU - Trama, A.
AU - Serraino, D.
AU - Zucchetto, A.
AU - De Angelis, R.
AU - Verne, J.
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Kidney cancer is a frequent malignant disease. To date, there is no evidence on the effectiveness of early detection and, in most cases, surgery represents the only standard treatment. So far, there is no standardized therapy for localized and locally advanced renal tumors; however, the recent introduction of target therapy has significantly improved the prognosis of metastatic disease. Therefore, survival differences in Europe are deemed to involve differences in diagnostic and therapeutic approaches. The aim of the SUDCAN collaborative study was to compare the net survival from kidney cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analysis, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modeling strategy. In 2000-2004, the 5-year net survival ranged between 59% (Spain) and 67%(France and Italy) in men and between 60% (Spain) and 73% (Portugal) in women. There was an increase in the age-standardized net survival between 1992 and 2004 at 1 year, as well as at 5 years, in all age groups and countries. Irrespective of the year of diagnosis, the excess mortality rate decreased with time elapsed since diagnosis. There are some differences in survival from kidney cancer between European Latin countries, but a considerable improvement was observed in most countries.
AB - Kidney cancer is a frequent malignant disease. To date, there is no evidence on the effectiveness of early detection and, in most cases, surgery represents the only standard treatment. So far, there is no standardized therapy for localized and locally advanced renal tumors; however, the recent introduction of target therapy has significantly improved the prognosis of metastatic disease. Therefore, survival differences in Europe are deemed to involve differences in diagnostic and therapeutic approaches. The aim of the SUDCAN collaborative study was to compare the net survival from kidney cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analysis, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland, and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modeling strategy. In 2000-2004, the 5-year net survival ranged between 59% (Spain) and 67%(France and Italy) in men and between 60% (Spain) and 73% (Portugal) in women. There was an increase in the age-standardized net survival between 1992 and 2004 at 1 year, as well as at 5 years, in all age groups and countries. Irrespective of the year of diagnosis, the excess mortality rate decreased with time elapsed since diagnosis. There are some differences in survival from kidney cancer between European Latin countries, but a considerable improvement was observed in most countries.
KW - Cancer registries
KW - Europe
KW - Excess mortality rate
KW - Kidney cancer
KW - Net survival
KW - Trend analysis
UR - http://www.scopus.com/inward/record.url?scp=85010214393&partnerID=8YFLogxK
U2 - 10.1097/CEJ.0000000000000297
DO - 10.1097/CEJ.0000000000000297
M3 - Article
C2 - 28005615
AN - SCOPUS:85010214393
SN - 0959-8278
VL - 26
SP - S121-S127
JO - European Journal of Cancer Prevention
JF - European Journal of Cancer Prevention
IS - Trends in cancer net survival in six European Latin Countries...
ER -